Key result
Routine therapeutic drug monitoring of dabigatran was associated with a subsequent change in dabigatran prescribing in 30% (68/233) of assay results.
Why the study?
To describe the routine clinical use over time, indications for testing, and subsequent prescribing decisions following the availability of a liquid chromatography-mass spectrometry dabigatran assay.
Does routine therapeutic drug monitoring of dabigatran influence prescribing decisions in clinical practice?
Observational (n=233)
Yes
Does routine therapeutic drug monitoring of dabigatran influence prescribing decisions in clinical practice?
Routine therapeutic drug monitoring of dabigatran frequently leads to dose adjustments, particularly in cases of uncertain renal function or drug interactions.
Answers are grounded in this paper and cite their sources.
May inform dabigatran dosing in select cases with uncertain renal function or interactions; leaves open outcome benefits and need for randomized trials.
BACKGROUND: A liquid chromatography-mass spectrometry assay to determine plasma dabigatran concentrations has been available for routine clinical use at our tertiary institutions since 2017. The aim of the study was to describe (1) the use of the assay over time; (2) the indications for testing; and (3) subsequent dabigatran prescribing decisions. METHODS: Patients for whom dabigatran concentrations were measured were identified using the laboratory database, and clinical data were extracted from the associated electronic health records. RESULTS: There were 233 samples in 24 months. The use of dabigatran increased over time, with a mean (95% confidence interval) increase of +0.5 (0.3-0.7) samples per month. Dabigatran concentrations ranged from <1 to 1060 mcg/L. The main reasons for testing were uncertainty about impact on renal function and drug interactions (39%), to inform prescribing decisions after thromboembolic or bleeding events (21%), and for investigation following dose-adjustment (16%). Dabigatran dose was changed after 30% (68/233) of assay results. CONCLUSIONS: The clinical use of the dabigatran assay has increased, with almost one-third of results associated with a subsequent change in dabigatran prescribing.
No takes yet. Share an insight, caveat, or question.
Chin et al. (2019) conducted an observational in Patients receiving dabigatran (n=233). Therapeutic drug monitoring of dabigatran was evaluated on Change in dabigatran prescribing decisions. Routine therapeutic drug monitoring of dabigatran was associated with a subsequent change in dabigatran prescribing in 30% (68/233) of assay results.
Synapse has enriched 10 related papers. Consider them for comparative context: